Targeted Radiation Therapy Resolves Dangerous Low Blood Sugar in 93% of Malignant Insulinoma Patients
Peptide receptor radionuclide therapy (PRRT) resolved life-threatening hypoglycemia in 93% of malignant insulinoma patients, with median overall survival of 50 months.
Quick Facts
What This Study Found
PRRT with Lu-177 DOTATATE resolved hypoglycemia in 93% of patients (14/15) after a median of 2.5 months, with median overall survival of 50.1 months and successful re-treatment in all recurrence cases.
Key Numbers
15 patients (7 female, median age 60). Median 7 cycles (range 1-15), median cumulative 42 GBq (range 4-117). 93% (14/15) had hypoglycemia resolution at median 2.5 months. Recurred in 7/14 at median 17.7 months. Recurrence group: more G3 (57% vs 0%), longer time to resolution (3.0 vs 0.5 months).
How They Did This
Retrospective review of 15 consecutive malignant insulinoma patients treated with PRRT at two Australian neuroendocrine tumor centers from 2004 to 2022.
Why This Research Matters
Malignant insulinoma is life-threatening primarily because of uncontrollable hypoglycemia. PRRT addresses both the tumor and the dangerous metabolic symptoms, providing a critical treatment option for patients who have exhausted other therapies.
The Bigger Picture
This is one of the largest published cohorts of PRRT for malignant insulinoma. The results support PRRT as a viable treatment option for this rare but dangerous cancer, adding to the evidence base for peptide-targeted radiotherapy in neuroendocrine tumors.
What This Study Doesn't Tell Us
Retrospective design, small sample size (n=15), single-arm without comparison group. Patient heterogeneity in tumor grade and treatment protocols. Hypoglycemia flare during treatment required hospitalization in nearly half of patients.
Questions This Raises
- ?Can earlier initiation of PRRT prevent the severe hypoglycemia episodes seen in higher-grade tumors?
- ?Would combination with newer targeted agents improve progression-free survival beyond 18 months?
Trust & Context
- Key Stat:
- 93% hypoglycemia resolution 14 of 15 malignant insulinoma patients had their life-threatening low blood sugar resolved by targeted peptide radiation therapy
- Evidence Grade:
- Retrospective case series — the strongest evidence feasible for a rare cancer. No randomized trials exist for this indication, making this one of the most informative datasets available.
- Study Age:
- Published in 2025, covering 18 years of clinical experience (2004-2022) at two specialized centers.
- Original Title:
- Peptide receptor radionuclide therapy in malignant insulinoma.
- Published In:
- Endocrine-related cancer, 32(6) (2025)
- Authors:
- Pattison, David A, Kong, Grace(2), Akhurst, Timothy, Burge, Matthew, Chiang, Cherie, Hofman, Michael S, Hung, Te-Jui, Love, Amanda, Michael, Michael, Okano, Satomi, Ravi Kumar, Aravind S, Sachithanandan, Nirupa, Wyld, David, Hicks, Rodney J
- Database ID:
- RPEP-12987
Evidence Hierarchy
Looks back at existing records to find patterns.
What do these levels mean? →Frequently Asked Questions
What is PRRT and how does it treat insulinoma?
PRRT (peptide receptor radionuclide therapy) attaches radioactive material to a peptide that specifically targets tumor cell receptors. When injected, the peptide homes to the tumor and delivers targeted radiation directly to cancer cells, sparing most healthy tissue.
Did the low blood sugar come back after treatment?
In half of the patients who initially responded, hypoglycemia recurred after a median of about 18 months. However, re-treatment with PRRT was successful in all cases, providing continued disease control.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-12987APA
Pattison, David A; Kong, Grace; Akhurst, Timothy; Burge, Matthew; Chiang, Cherie; Hofman, Michael S; Hung, Te-Jui; Love, Amanda; Michael, Michael; Okano, Satomi; Ravi Kumar, Aravind S; Sachithanandan, Nirupa; Wyld, David; Hicks, Rodney J. (2025). Peptide receptor radionuclide therapy in malignant insulinoma.. Endocrine-related cancer, 32(6). https://doi.org/10.1530/ERC-25-0018
MLA
Pattison, David A, et al. "Peptide receptor radionuclide therapy in malignant insulinoma.." Endocrine-related cancer, 2025. https://doi.org/10.1530/ERC-25-0018
RethinkPeptides
RethinkPeptides Research Database. "Peptide receptor radionuclide therapy in malignant insulinom..." RPEP-12987. Retrieved from https://rethinkpeptides.com/research/pattison-2025-peptide-receptor-radionuclide-therapy
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.